The effects of pretreatment with nitroglycerin on ischemic left ventricular dysfunction during coronary angioplasty. 1991

I Amende, and G Herrmann, and R Simon, and W P Hood, and P Wenzlaff, and P R Lichtlen
Department of Cardiology, Medical University Hannover, FRG.

To evaluate the degree to which nitroglycerin reduces myocardial ischemia and dysfunction induced by transient coronary occlusion, 19 patients were studied during coronary angioplasty of the left anterior descending coronary artery. After a control occlusion of 60 seconds, 0.2 mg nitroglycerin was administered intravenously and the occlusion was repeated for 60 seconds. Before and during the occlusion period, pulmonary capillary wedge pressure was measured, the intracoronary ECG was recorded, and ventricular volumes, ejection fraction, and regional systolic shortening were obtained by digital subtraction angiography. Nitroglycerin caused a significant fall in pulmonary capillary wedge pressure before (10 vs. 7 mmHg) and at 60 seconds occlusion (18 vs. 14 mmHg), but did not significantly delay the rise in wedge pressure (37 vs. 44 seconds). End-systolic left ventricular volume at 60 seconds of occlusion was reduced by nitroglycerin (77 vs. 68 ml), whereas regional shortening of the ischemic segments remained unchanged (22 vs. 23%). Nitroglycerin did not delay the onset of ischemic ST-segment elevation (14 vs. 14 seconds) and had no effect on the changes of ST elevation in the intracoronary ECG (1.9 vs. 1.9 mV). These findings suggest that intravenous nitroglycerin reduces filling pressure and slightly improves left ventricular global function during acute coronary occlusion. Nitroglycerin, however, has little effect on ischemia-induced regional dysfunction and on ST-segment elevation in the intracoronary ECG.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011292 Premedication Preliminary administration of a drug preceding a diagnostic, therapeutic, or surgical procedure. The commonest types of premedication are antibiotics (ANTIBIOTIC PROPHYLAXIS) and anti-anxiety agents. It does not include PREANESTHETIC MEDICATION. Premedications
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005260 Female Females
D005996 Nitroglycerin A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives. Glyceryl Trinitrate,Anginine,Dynamite,Gilustenon,Nitrangin,Nitro-Bid,Nitro-Dur,Nitrocard,Nitroderm,Nitroderm TTS,Nitroglyn,Nitrol,Nitrolan,Nitrong,Nitrospan,Nitrostat,Perlinganit,Susadrin,Sustac,Sustak,Sustonit,Transderm Nitro,Tridil,Trinitrin,Trinitrolong,Nitro Bid,Nitro Dur,NitroBid,NitroDur,Trinitrate, Glyceryl
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

I Amende, and G Herrmann, and R Simon, and W P Hood, and P Wenzlaff, and P R Lichtlen
October 1990, Journal of the American College of Cardiology,
I Amende, and G Herrmann, and R Simon, and W P Hood, and P Wenzlaff, and P R Lichtlen
December 1993, The American journal of cardiology,
I Amende, and G Herrmann, and R Simon, and W P Hood, and P Wenzlaff, and P R Lichtlen
October 1998, The American journal of cardiology,
I Amende, and G Herrmann, and R Simon, and W P Hood, and P Wenzlaff, and P R Lichtlen
April 1990, Circulation,
I Amende, and G Herrmann, and R Simon, and W P Hood, and P Wenzlaff, and P R Lichtlen
June 1991, The American journal of cardiology,
I Amende, and G Herrmann, and R Simon, and W P Hood, and P Wenzlaff, and P R Lichtlen
July 2002, Clinical cardiology,
I Amende, and G Herrmann, and R Simon, and W P Hood, and P Wenzlaff, and P R Lichtlen
December 1986, Cardiologia (Rome, Italy),
I Amende, and G Herrmann, and R Simon, and W P Hood, and P Wenzlaff, and P R Lichtlen
August 1997, Circulation,
I Amende, and G Herrmann, and R Simon, and W P Hood, and P Wenzlaff, and P R Lichtlen
September 1990, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
I Amende, and G Herrmann, and R Simon, and W P Hood, and P Wenzlaff, and P R Lichtlen
September 1998, Cardiologia (Rome, Italy),
Copied contents to your clipboard!